VinFuture Prize holds the distinction of being the first major international science and technology award to recognize and ...

Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that poster presentations on preliminary studies of its oral small molecule GLP-1 Receptor (GLP-1R) agonist ASC30 and adipose-targeted, ...

Orforglipron (pronounced or-for-GLIP-ron) might be a mouthful to say, but Indianapolis-based Eli Lilly and Co. sees this ...

Onesource Specialty, a newly demerged pharma CDMO, is set to benefit from the $150 billion GLP-1 weight-loss drug boom with ...

Regeneron’s shares have declined nearly 17% following the failure of the company’s Dupixent follow-up itepekimab.

NVO advances obesity pipeline with CagriSema and Amycretin while expanding through major deals amid rising competition.

Weight-loss drugs like Ozempic and Wegovy are used by more than 15 million adults in the U.S., or 4.5% of the population.

Ozempic helped Novo Nordisk gain an early lead in the weight loss industry, but competition is nipping at the company's heels ...

Eli Lilly, Novo’s main rival for the obesity market, shared phase 3 data on a small-molecule GLP-1 in April. The readout suggested Lilly’s orforglipron can provide Ozempic-like efficacy in ...

Novo Nordisk’s stock has tumbled over 50% since its peak around a year ago, and it just ousted its CEO. Former employees say ...

Viking Therapeutics faces tough obesity drug rivals, with VK2735 showing promise but an uncertain edge. Find out why VKTX ...

Discover how the breakthrough pill orforglipron matches injectable weight loss drugs in effectiveness while offering ...